Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord

August 26, 2026 updated by: M.D. Anderson Cancer Center
To learn if MRS can effectively assess spinal cord lesions.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Primary Objective:

Establish the feasibility and spectrum of MRS for adult patients while mapping the total spine spectrum at short TEs to allow for future comparison with patients to assess spinal cord lesions malignant potential and grade.

Secondary Objective:

Test success of the spectrum by implementing the protocol on 3 low volume LMD receiving LMD receiving CSI. This will allow us to test reproducibility of the protocol and test effect of radiation on spinal cord at different time frames. This will serve as secondary data for subsequent trials targeting functional statues after radiation and tumor grading predictability of MRS.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77090
        • MD Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Volunteers:

  • Adults > 18 years
  • Healthy with no malignancy, demyelinating disease, back pain, degenerative disease, or spinal cord lesions.
  • Consent able patients.

Patients with low volume LMD to receive treatment CNS radiation:

  • Adults > 18 years old.
  • MR or CSF with evidence of LMD.
  • Patients to receive CSI as part of standard treatment of LMD disease.
  • Consent able patients, willingness and ability to comply with the study procedures.
  • No spinal cord lesions only LMD disease
  • Recruitment by radiation oncology faculty in consultation with Dr. De. . .

Exclusion Criteria:

Volunteers:

  • Age < 18 years
  • Pregnant or breastfeeding individuals.
  • History of cancer.
  • History of spinal cord lesions including malignant, demyelinating, or inflammatory.
  • History of prior spinal surgery.
  • History of implantable devices.
  • History of MR claustrophobia.
  • Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
  • Scoliosis.

Patients with LMD:

  • Age < 18 years
  • History of spinal cord lesions including malignant, demyelinating, or inflammatory.
  • History of prior spinal surgery.
  • History of implantable devices.
  • History of MR claustrophobia.
  • Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
  • Scoliosis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Healthy Volunteers
Participants will be recruited from DI volunteer pool to implement MRS spine on.
Diagnostic test: Magnetic Resonance Spectroscopy (MRS) Scan
Participants will receive MRS Scan
Experimental: Patients
Participants will be recruited from DI volunteer pool to implement MRS spine on.
Diagnostic test: Magnetic Resonance Spectroscopy (MRS) Scan
Participants will receive MRS Scan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and Adverse Events (AEs)
Time Frame: Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Through study completion; an average of 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Rami Eldaya, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 4, 2024

Primary Completion (Actual)

August 25, 2026

Study Completion (Actual)

August 25, 2026

Study Registration Dates

First Submitted

August 8, 2024

First Submitted That Met QC Criteria

August 8, 2024

First Posted (Actual)

August 12, 2024

Study Record Updates

Last Update Posted (Actual)

August 31, 2026

Last Update Submitted That Met QC Criteria

August 26, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024-0249
  • NCI-2024-06761 (Other Identifier: NCI-CTRP Clinical Trials Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe